Governance
Source and Citation Policy
Sources on this site are named, dated, and linked wherever possible. Clinical claims cite FDA labelling or a specific trial with its ClinicalTrials.gov identifier, PubMed identifier, and DOI. Commercial claims cite a dated capture of a named provider page. Citation-shaped phrases that name no source are prohibited, because they transfer confidence to a reader without transferring anything checkable.
Key takeaways
- Clinical claims cite a specific trial with NCT, PMID, and DOI, or FDA labelling.
- Commercial claims cite a dated capture from a named provider source.
- Vague attributions of the studies-show or widely-reported variety are prohibited.
- Where an identifier has not been verified, the numeric claim is withheld rather than cited loosely.
- Outbound source links are nofollow and open in a new tab; none are monetised.
| Clinical sources | FDA labelling, peer-reviewed literature, ClinicalTrials.gov |
|---|---|
| Identifier standard | NCT + PMID + DOI where a trial result is asserted |
| Commercial sources | Dated first-party capture of a named provider page |
| Regulatory sources | FDA, state boards of pharmacy |
| Prohibited | Studies-show, widely-reported, or experts-agree attributions without a named source |
Why require three identifiers for a trial?
Because each does a different job. The NCT number identifies the registered protocol, which reveals the design and endpoints as pre-specified. The PMID locates the peer-reviewed publication. The DOI provides a stable link to the article itself. Together they let a reader check not only what was published but whether it matches what was registered.
What counts as a citable source?
| Tier | Source type | Used for |
|---|---|---|
| 1 | FDA labelling and approved product information | Indications, warnings, contraindications |
| 1 | Peer-reviewed primary trial publications | Efficacy and safety results |
| 1 | ClinicalTrials.gov registry records | Design, population, endpoints, sponsor |
| 2 | State boards of pharmacy and regulatory notices | Licensure, facility status, enforcement |
| 3 | Dated first-party captures of provider pages | Pricing, fees, terms |
| — | Provider marketing claims without verification | Not cited as fact |
How much of this site's data is actually verified?
| Group | Records |
|---|---|
| Trials with full identifiers | 8 |
| Trials partially verified | 1 |
| Trials withheld pending audit | 1 |
| Providers with verified all-in price | 5 |
| Providers excluded with reason | 19 |
| Evidence status | Definition | What may be published |
|---|---|---|
| Verified | Checked against a primary source with a recorded date | The claim, with its identifier and date |
| Partially verified | Some elements confirmed, others outstanding | Confirmed elements only; the rest labelled |
| Verification Pending | Not yet checked against a primary source | No factual assertion — the gap is shown |
What does this page cover, and what does it deliberately leave out?
This page addresses FDA, labels, PubMed, ClinicalTrials.gov, boards and first-party captures, organised around the primary question of tirzepatide source policy. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Fda | Covered on this page | Regulatory or policy source |
| Labels | Covered on this page | Regulatory or policy source |
| Pubmed | Covered on this page | Regulatory or policy source |
| Clinicaltrials.gov | Covered on this page | Regulatory or policy source |
| Boards | Covered on this page | Regulatory or policy source |
| First-party captures | Covered on this page | Regulatory or policy source |
| Individualized clinical instruction | Deliberately not covered | Belongs with the corrections process |
What are the limits of what this page can tell you?
Every page on this site rests on a specific published policy, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the corrections process.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This page would be revised, with the change recorded in its history, if any of the following occurred:
- New primary evidence bearing directly on tirzepatide source policy.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 5 technical terms this page uses, including DOI, NCT number, PMID, contraindication — in the specific sense used above.
| DOI | Digital Object Identifier. A persistent link to a specific published article that continues to resolve even if the journal reorganises its website. |
|---|---|
| NCT number | The identifier assigned to a study registered on ClinicalTrials.gov. It allows a reader to check the pre-specified design and endpoints against what was eventually published. |
| PMID | PubMed Identifier. A number that locates the peer-reviewed publication of a study in the PubMed database. |
| contraindication | A circumstance in which a drug should not be used at all. For tirzepatide these include a personal or family history of medullary thyroid carcinoma and MEN2. |
| endpoint | The outcome a trial is designed to measure. A primary endpoint is specified before the trial begins; secondary and exploratory endpoints carry progressively weaker inferential weight. |
Frequently asked questions
What sources do you cite for clinical claims?
FDA labelling and specific trials identified by NCT, PMID, and DOI.
How are provider prices sourced?
From a dated capture of a named provider page, with the capture date shown.
Why avoid studies-show phrasing?
Because they imply a citation without providing one and cannot be checked.
Are source links monetised?
No. All outbound links are nofollow and earn nothing.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.